· Published by Health Canada · Official notice
This is duplicated text of a letter from Novartis Pharmaceuticals Canada Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
November 6, 2012
Subject: Health Canada lifts the suspension of distribution of AGRIFLU® and FLUAD® seasonal flu vaccines
Dear Patient:
Novartis Pharmaceuticals Canada Inc. ("Novartis"), in collaboration with Health Canada would like to inform you that the review of the safety information for AGRIFLU® and FLUAD® is now complete and Health Canada has released the two seasonal flu vaccines for immediate use.
Health Canada asked Novartis to stop distribution of AGRIFLU® and FLUAD® as a precautionary measure, while they performed additional testing and reviewed additional data on some particles found in some of the vaccines. These particles were found to be clusters of protein, referred to as aggregates (protein from the surface of the virus which creates the body's immune response). These proteins are normal components of influenza vaccines. Protein aggregates can occur in the vaccines manufacturing process and do not pose a risk to health. This review by Health Canada is now complete and health care professionals can start using these vaccines once again.
AGRIFLU® is an inactivated influenza subunit virus vaccine for immunization against influenza, indicated for everyone aged 6 months and older. It has been sold throughout Europe as AGRIPPAL® since 1998.
FLUAD® is an adjuvanted inactivated influenza virus vaccine, specifically indicated in adults 65 years of age and older. FLUAD® contains the adjuvant MF59™, which helps increase antibody production and improve immune response in the elderly. It has more than 12 years of clinical experience and more than 60 million doses have been distributed worldwide.
Novartis manufactures AGRIFLU® and FLUAD® in Italy and distributes them in Canada by Novartis Pharmaceuticals Canada Inc.
This public communication will be made available on Novartis' website.
Please refer to Health Canada's Web site for more information.
Managing marketed health product-related adverse events is dependent upon health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse events are generally presumed to underestimate the risks associated with health product treatments. Should you experience an adverse event following immunization, please ask your doctor, nurse, or pharmacist to complete the Adverse Events following Immunization (AEFI) Form or report it to Novartis at:
Novartis Pharmaceuticals Canada Inc.
385 Bouchard Blvd.,
Dorval, QC H9S 1A9
e-mail address: drug.safety@novartis.com
Telephone: 1-877-631-6775 EXT. 3425
How to report a suspected Adverse Event following Immunization:
Should you experience an adverse event following immunization, please ask your doctor, nurse, or pharmacist to complete the Adverse Events following Immunization (AEFI) Form.
The Adverse Events Following Immunization Reporting Form and Guidelines can be found on the Public Health Agency of Canada Web site or in the Canadian Compendium of Pharmaceuticals and Specialties.
If you have any questions or have difficulties contacting your local health department, please contact the Vaccine Safety Section at the Public Health Agency of Canada at:
Telephone: 613-954-5590, 1-866-844-0018
Fax: 613-954-9874; 1-866-844-5931
Should you require additional medical information regarding the use of AGRIFLU® and FLUAD®, please contact Novartis Medical Information at 1-800-363-8883.
Sincerely,
original signed by
Jean Godin, M.D.
Chief Scientific Officer and Vice-President
Clinical and Regulatory Affairs
Novartis Pharmaceuticals Canada Inc.